LoginSignup
TEN

Tenax Therapeut

Stock
Stock
ISIN: US88032L6056
Ticker: TENX
US88032L6056
TENX

Price

Price

Frequently asked questions

What is Tenax Therapeut's market capitalization?

The market capitalization of Tenax Therapeut is $16.53M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Tenax Therapeut?

Tenax Therapeut's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$15.92. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Tenax Therapeut's stock?

Currently, 1 analysts cover Tenax Therapeut's stock, with a consensus target price of $32.50. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Tenax Therapeut?

Tenax Therapeut's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$15.54M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Tenax Therapeut?

Tenax Therapeut has a free cash flow of -$12.46M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Tenax Therapeut's stock?

The 5-year beta for Tenax Therapeut is 2.18. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Tenax Therapeut have, and what sector and industry does it belong to?

Tenax Therapeut employs approximately 5 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Tenax Therapeut's shares?

The free float of Tenax Therapeut is 3.40M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $16.53M

5Y beta

 2.18

EPS (TTM)

 -$15.92

Free Float

 3.40M

EBITDA (TTM)

 -$15.54M

Free Cashflow (TTM)

 -$12.46M

Pricing

52W span
$2.77$33.44

Analyst Ratings

The price target is $32.50 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

5

Biotechnology & Drugs

Health Care

Identifier

ISIN

US88032L6056

Primary Ticker

TENX
Join the conversation
Sign upLogin